Leveraging our unparalleled expertise in diseases of the immune system and CXCR4 biology, we aim to bring innovative treatments to patients with chronic neutropenic disorders.

Our lead product candidate, mavorixafor, is a first-in-class CXCR4 inhibitor being developed as a once-daily, oral therapy for people with chronic neutropenic disorders. Mavorixafor has demonstrated the ability to mobilize immune cells from the bone marrow into the bloodstream, creating what we believe to be broad commercial potential in the estimated 50,000 (U.S.) diagnosed chronic neutropenia patients who currently have few to no treatment options.

We are currently evaluating the safety and efficacy of mavorixafor in a Phase 3 clinical trial for the treatment of people with WHIM syndrome; data from this Phase 3 study (4WHIM) are expected in the fourth quarter of 2022. We are also conducting a Phase 1b clinical trial of mavorixafor in people with idiopathic, cyclic, or congenital neutropenia. Based on positive data from the first part of this Phase 1b trial, we are currently amending and expanding the study to evaluate chronic use of daily oral mavorixafor with or without G-CSF in up to 50 participants with chronic neutropenic disorders. 

X4 is a public biopharmaceutical company (Nasdaq: XFOR) headquartered in Boston, Massachusetts, with a research center of excellence in Vienna, Austria.



Sio Capital Management

Abingworth

Altium Capital

Bain Capital Life Sciences

Lincoln Park Capital Fund

Monashee Investment Management

OrbiMed

Driehaus Capital Management

Ikarian Capital

X4 Pharmaceuticals

X4 was proud to participate in the American Society of Hematology #ASH23 conference and remains committed to raising awareness of #WHIMsyndrome, and the importance of early diagnosis, in the #hematology community.
 
If you suspect a patient could have WHIM syndrome, connect with X4 and access diagnosis resources at bit.ly/3FFTZTn
 
#classicalheme #hemeonc #immunology #immunedeficiency #WhatIfItsWHIM #chronicneutropenia #raredisease

This week, X4 is at the American Society of Hematology #ASH23 conference, connecting with hematologists to share disease education resources for diagnosing #WHIMsyndrome. WHIM is a rare hematologic disorder that may lead to debilitating or life-threatening complications.

Visit us at Booth 501 or find diagnosis resources including details about no-cost genetic testing at bit.ly/3FEoCbQ

#raredisease #hematology #classicalheme #hemeonc #immunology #immunedeficiency #WhatIfItsWHIM #chronicneutropenia


X4 is proud to be at the American Society of Hematology #ASH23 conference to raise awareness of #WHIMsyndrome and provide disease education resources to help facilitate diagnosis of patients living with this chronic hematologic disorder and combined primary immunodeficiency.

WHIM syndrome is a #raredisease frequently characterized by #chronicneutropenia, lymphopenia, recurrent infections, and hypogammaglobulinemia, with signs and symptoms that vary from patient to patient.

To learn more, visit us at Booth 501 or at bit.ly/3s8PkX8
#hematology #classicalheme #hemeonc #immunology #immunedeficiency #WhatIfItsWHIM



Are you attending the 65th American Society of Hematology annual meeting? Be sure to stop by our sponsored Industry Theater, “Classical Hematology: Looking Into the Future” on December 10th from 8:00 AM – 9:00 AM PST. Hope to see you there! #ASH23 

Thank you to The Boston Globe for recognizing us as a 2023 Top Place to Work! #X4tizens are the driving force behind what makes X4 exceptional. This recognition reflects our shared values as we bring hope to people with #rarediseases. Learn more here: https://brnw.ch/21wEWrj

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

NASDAQ:XFOR

X4 Pharmaceuticals

Last Close

0.69

30/08 20:00

Market Cap

103.11M

Beta: 0.25

Volume Today

726.85K

Avg: 1.81M

PE Ratio

−1.27

PFCF: −1.65